



US008951985B2

(12) **United States Patent**
Surleraux et al.

(10) **Patent No.:** **US 8,951,985 B2**
(45) **Date of Patent:** **Feb. 10, 2015**

(54) **COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS**

(75) Inventors: **Dominique Surleraux**, Wauthier-Braine (BE); **Cyril B. Dousson**, Canet (FR); **David Dukhan**, Saint Gely du Fesc (FR); **Claire Pierra**, Montarnaud (FR)

(73) Assignee: **Idenix Pharmaceuticals, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 293 days.

(21) Appl. No.: **13/610,574**

(22) Filed: **Sep. 11, 2012**

(65) **Prior Publication Data**

US 2013/0064793 A1 Mar. 14, 2013

Related U.S. Application Data

(60) Provisional application No. 61/533,704, filed on Sep. 12, 2011.

(51) **Int. Cl.**
A01N 43/04 (2006.01)
A61K 31/70 (2006.01)
C07H 19/207 (2006.01)

(52) **U.S. Cl.**
CPC **C07H 19/207** (2013.01)
USPC **514/47**; 514/43; 514/45; 514/46;
514/49; 514/50; 514/51

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,026,687 A 6/1991 Yarchoan et al.
5,118,672 A 6/1992 Schinazi et al.
5,149,794 A 9/1992 Yatvin et al.
5,455,339 A 10/1995 Chu et al.
5,496,546 A 3/1996 Wang et al.
5,538,865 A 7/1996 Reyes et al.
5,610,054 A 3/1997 Draper et al.
5,633,358 A 5/1997 Gruetzke et al.
5,633,388 A 5/1997 Diana et al.
5,725,859 A 3/1998 Omer et al.
5,830,905 A 11/1998 Diana et al.
5,837,257 A 11/1998 Tsai et al.
5,846,964 A 12/1998 Ozeki et al.
5,869,253 A 2/1999 Draper et al.
5,891,874 A 4/1999 Colacino et al.
5,922,757 A 7/1999 Chojkier et al.
5,990,276 A 11/1999 Zhang et al.
6,004,933 A 12/1999 Spruce et al.
6,034,134 A 3/2000 Gold et al.
6,043,077 A 3/2000 Barber et al.
6,056,961 A 5/2000 Lavie et al.
6,071,922 A 6/2000 Schinazi et al.
6,265,380 B1 7/2001 Tung et al.
6,323,180 B1 11/2001 Llinas-Brunet et al.
6,348,587 B1 2/2002 Schinazi et al.
6,410,531 B1 6/2002 Llinas-Brunet et al.
6,420,380 B2 7/2002 Llinas-Brunet et al.
6,534,523 B1 3/2003 Llinas-Brunet et al.
6,642,204 B2 11/2003 Llinas-Brunet et al.

6,653,295 B2 11/2003 Glunz et al.
6,660,721 B2 12/2003 Devos et al.
6,727,366 B2 4/2004 Han et al.
6,777,395 B2 8/2004 Bhat et al.
6,784,166 B2 8/2004 Devos et al.
6,838,475 B2 1/2005 Arasappan et al.
6,846,810 B2 1/2005 Martin et al.
6,867,185 B2 3/2005 Campbell et al.
6,869,964 B2 3/2005 Campbell et al.
6,872,805 B2 3/2005 Campbell et al.
6,878,722 B2 4/2005 Campbell et al.
6,911,428 B2 6/2005 Zhu et al.
6,927,291 B2 8/2005 Jin et al.
6,995,174 B2 2/2006 Wang et al.
7,041,698 B2 5/2006 Ripka et al.
7,091,184 B2 8/2006 Llinas-Brunet et al.
7,094,770 B2 8/2006 Watanabe et al.
7,105,499 B2 9/2006 Carroll et al.
7,125,855 B2 10/2006 Bhat et al.
7,169,760 B2 1/2007 Saksena et al.
7,202,224 B2 4/2007 Eldrup et al.
7,208,600 B2 4/2007 Cottrell et al.
7,429,572 B2 9/2008 Clark
7,601,820 B2 10/2009 Wang et al.
7,608,600 B2 10/2009 Storer et al.
2002/0120129 A1 8/2002 Beigelman et al.
2004/0121980 A1 6/2004 Martin et al.
2004/0209831 A1 10/2004 McSwiggen et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 19914474 10/1999
GB 1209654 10/1970

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 60/392,350, filed Jun. 28, 2002, Sommadossi.
U.S. Appl. No. 60/466,194, filed Apr. 28, 2003, Sommadossi.
U.S. Appl. No. 60/470,949, filed May 14, 2003, Sommadossi.
U.S. Appl. No. 60/474,368, filed May 30, 2003, Clark.
U.S. Appl. No. 10/608,907, filed Jun. 27, 2003, Sommadossi.
U.S. Appl. No. 11/854,218, filed Sep. 12, 2007, Clark.
U.S. Appl. No. 12/131,868, filed Jun. 2, 2008, Sommadossi.
U.S. Appl. No. 12/878,262, filed Sep. 9, 2010, Clark.
Interference 105,871, Notice to Declare Interference dated Feb. 22, 2012.
Interference 105,871, Sommadossi Claims dated Mar. 7, 2012.
Interference 105,871, Sommadossi Notice of Real Parties in Interest dated Mar. 7, 2012.
Interference 105,871, Sommadossi Notice of Related Proceedings dated Mar. 7, 2012.
Interference 105,871, Sommadossi File Copy Request dated Mar. 7, 2012.

(Continued)

Primary Examiner — Patrick Lewis
(74) *Attorney, Agent, or Firm* — Jones Day

(57) **ABSTRACT**

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

22 Claims, No Drawings